Disruption of Supply

4th Mar 2005 16:10

GlaxoSmithKline PLC04 March 2005 GSK Announces Disruption of Supply for Paxil CR and Avandamet March 4, 2005 - GlaxoSmithKline (GSK) said today that the US Food and DrugAdministration has halted distribution of supplies of two of its medicines dueto manufacturing issues: Avandamet (rosiglitazone maleate / metforminhydrochloride) tablets, used to treat type 2 diabetes, and Paxil CR (paroxetinehydrochloride controlled release) tablets, a treatment for depression andseveral anxiety disorders. The FDA action relates to all strengths of Paxil CR (12.5 mg, 25 mg, and 37.5mg) as well as Avandamet (1 mg, 2 mg, and 4 mg). In the short term, it isexpected that the FDA action will result in a shortage of patient supplies forboth of these medicines. GSK believes that the manufacturing issues do not pose a health risk topatients. GSK agrees with the FDA that patients who use these two medicinesshould continue taking their tablets and talk with their healthcare provider ifthey have questions. The company is working with the FDA to resolve these issues as quickly aspossible. S M BicknellCompany Secretary 4 March 2005 GlaxoSmithKline - one of the world's leading research-based pharmaceutical andhealthcare companies - is committed to improving the quality of human life byenabling people to do more, feel better and live longer. For company informationvisit www.gsk.com. ________________________________________________________________________________ Enquiries: UK Media Philip Thomson (020) 8047 5502 David Mawdsley (020) 8047 5502 Chris Hunter-Ward (020) 8047 5502 US Media Nancy Pekarek (215) 751 7709 Mary Anne Rhyne (919) 483 2839 Patricia Seif (215) 751 7709 European Analyst / Investor Duncan Learmouth (020) 8047 5540 Anita Kidgell (020) 8047 5542 US Analyst / Investor Frank Murdolo (215) 751 7002 Tom Curry (215) 751 5419 ________________________________________________________________________________ This information is provided by RNS The company news service from the London Stock Exchange

---

Related Shares:

Glaxosmithkline